Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of liver cancer research and CAR-T therapy development, reflecting growing industry interest in Oricell’s Ori-C101 data for late-line hepatocellular carcinoma.
Pharma & Biotech

Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Read More
Representative image showing a biotech licensing discussion around long-acting GLP-2 therapy, reflecting Lilly and Hanmi Pharm’s sonefpeglutide deal for short bowel syndrome treatment.
Pharma & Biotech

Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?

Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.

Read More
Representative image: Genentech’s obesity drug data update at ADA 2026 underscores rising interest in enicepatide, petrelintide and next-generation weight management therapies.
Pharma & Biotech

Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?

Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.
Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More
Representative image of oncology researchers analysing cancer imaging and laboratory data as SalubrisBio’s JK06 antibody drug conjugate shows early Phase 1/2 promise in 5T4-targeted treatment for lung cancer and breast cancer.
Pharma & Biotech

SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?

Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.

Read More
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Pharma & Biotech

Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3

Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.

Read More
Pharma & Biotech

TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Read More